Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3499-3505

  Voigt, W ^a,b,c   Matsui, S ^c   Yin, M B ^c   Burhans, W C ^c   Minderman, H ^c   Rustum, Y M ^c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chromesomal damage; DNA synthesis; SN 38; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; IRINOTECAN;

ARTICLE; CELL CYCLE S PHASE; CHROMATID; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

CAMPTOTHECIN; CHROMATIDS; CHROMOSOME ABERRATIONS; DNA DAMAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; S PHASE; SISTER CHROMATID EXCHANGE; TUMOR CELLS, CULTURED;

EID: 0031790615     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chen AY and Liu LF: DNA Topoisomerases: Essential Enzymes and Lethal Targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994.
2. Brill SJ, DiNardo S, Voelkel-Meiman K and Sternglanz R: Need for DNA topoisomerase 1 activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature 326: 414-416, 1987.
3. Lima DC, Wang JC and Mondragon A: Three-dimensional structure of the 67K N-terminal fragment of E.coli DNA topoisomerase I. Nature 367: 138-145, 1994.
4. Knab AM, Fertala J and Bjornsti MA: A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase I Poisons. J Biol Chem 270: 6141-6148, 1995.
5. Trask DK and Muller MT: Stabilization of topoisomerase I-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci 85: 1417-1421, 1988.
6. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin Induces Protein-linked DNA Breaks via Mammalian DNA Topoisomerase I. J Biol Chem 27: 14873-14878, 1985.
7. Avemann K, Knippers R, Koller T and Sogo JM: Camptothecin, a Specific Inhibitor of Type I DNA Topoisomerase, Induces DNA Breakage at Replication Forks. Mol Cell Biol 8: 3026-3034, 1988.
8. Shin GC and Snapka RM: Exposure To Camptothecin Breaks Leading And Lagging Strand Siman Virus DNA Replication Forks. Biochem Biophys Res Comm 168: 135-140, 1990.
9. cdc2/Cyclin B. Cancer Res 52: 1823-1829, 1992.
10. Goldwasser F, Bac I, Valenti M, Torres K, Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res 55: 2116-2121, 1995.
11. Ryan AJ, Squires S, Strutt HL and Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295-3300, 1991.
12. Ryan AJ, Squires S, Strutt HL, Evans A and Johnson TR: Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis 15: 823-828, 1994.
13. Beidler DR and Cheng YC: Camptothecin Induction of a Time-and Concentration-Dependent Decrease of Topoisomerase I and Its Implication in Camptothecin Activity. Mol Pharmacol 47: 907-914, 1995.
14. O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW and Pommier Y: S-Phase Population Analysis Does Not Correlate with the Cytotoxicity of Camptothecin and 10,11-Methylenedioxycamptothecin in Human Colon Carcinoma HT-29 Cells. Cancer Commun 3: 233-240, 1991.
15. Kaufmann WK, Boyer JC, Estabrooks LL and Wilson SJ: Inhibition of Replicon Initiation in Human Cells Following Stabilisation of Topoisomerase-DNA Cleavable Complexes. Mol Cell Biol 11: 3711-3718, 1991.
16. Stewart FA and Schuetz G: Camptothecin-Induced In Vivo Topoisomerase I Cleavages in the Transcriptionally Active Tyrosine Aminotransferase Gene. Cell 50: 1109-1117, 1987.
17. Zhang H, Wang JC and Liu LF: Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci 85: 1060-1064, 1988.
18. Morris EJ, Geller HM: Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: Evidence for cell cycle-independent toxicity. J Cell Biol 131: 757-770, 1996.
19. Degrassi F, Desalvia R, Tanzarella R, Palitti F: Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutation Res 211: 125-130, 1989.
20. Andersson HC and Kihlman BA: Induction of chromosomal aberrations by camptothecin in root-tip cells of Vicia faba. Mutation Res 268: 167-181, 1992.
21. Creemerst GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treatment Reviews 20: 73-96, 1994.
22. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F and Pommier Y: Differential Stabilization of Eukaryotic DNA Topoisomerase I Cleavable Complexes by Camptothecin Derivates. Biochemistry 34: 7200-7206, 1995.
23. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y: Comparison of Topoisomerase I inhibition, DNA Damage and Cytotoxicity of Camptothecin Derivates Presently in Clinical Trials. J Nat Cancer Inst 86: 836-842, 1994.
24. Holm C, Covey JM, Kerrigan D, Pommier Y: Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese Hamster DC3F cells. Cancer Res 49: 6365-6368, 1989.
25. D'Arpa P, Beardmore C and Liu LF: Involvement of Nucleic Acid Synthesis in Cell Killing Mechanism of Topoisomerase Poisons. Cancer Res 50: 6919-69247 1990.
26. Maul GG, French BT, Venrooij van WJ and Jimenez SA: Topoisomerase I identified by scleroderma 70 antisera: Enrichment of topoisomerase I at the centromere in mouse cells before anaphase. Proc Natl Acad Sci 83: 5145-5149, 1986.
27. Pommier Y, Jenkins J, Kohlhagen G, Leteurtre F: DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutation Res 337(2): 135-145, 1995.
28. Jaxel C, Capranica G, Kerrigan D, Kohn KW, and Pommier Y: Effect of local DNA sequences on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266: 20418-20423, 1991.
29. Fujimori A, Harker G, Kohlhagen G, Hoki Y, and Pommier Y: Mutation at the calaytic site of topoisomerase I in CEM/C2, a human leukemic cell line resistant to camptothecin. Cancer Res 55: 1339-1346, 1995.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyed MR: New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J Natl Cancer Inst 82: 1107-1112, 1990
31. Finney M. Current Protocols in Molecular Biology. (Edit. Abusubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J. G., Smith, J. A. & Struhl, K.). Wiley, New York. pp. 2.5.11-15, 1989
32. Schwartz DC and Cantor CR: Separation of Yeast Chromosome-Sized DNAs by Pulsed Field Gradient Gel Electrophoresis. Cell 37: 67-75, 1984.
33. Woyrianowski JM, Sigmund RD and Beerman TA: Topoisomerase II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivates, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA. Biochim Biophys Acta 950: 21-29, 1988.
34. Perry P and Wolff S: New Giemsa method for the differential staining of sister chromatids. Nature 251: 156-158, 1974.
35. Shiraishi Y, Matsui S and Sandberg AA: Normalization by cell fusion of SCE in Bloom syndrome lymphocytes. Science 212: 820-822, 1981.